More recently, the same group reported on the development of a pan-cancer multi-analyte screening test, called CancerSEEK, capable of detecting somatic mutations across 16 genes in ctDNA (including KRAS), and quantifying 8 cancer-associated proteins (carbohydrate antigen 125 (CA-125), CA19-9, CEA, HGF, myeloperoxidase, prolactin, OPN, tissue inhibitor of metalloproteinases 1 (TIMP-1)) in blood [32]. This evidence concerns the gene PRL and cancer.